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DObjective: Recent advances in perioperative care have led to a decrease in mortality of children with hypoplastic
left heart syndrome undergoing the Norwood operation. This study aimed to evaluate the outcome of the Nor-
wood operation in a single center over 12 years and to identify clinical and anatomic risk factors for adverse early
and longer term outcome.
Methods: Full data on all 157 patients treated between 1996 and 2007 were analyzed.
Results: Thirty-day mortality of the Norwood operation decreased from 21% in the first 3 years to 2.5% in the
last 3 years. The estimated exponentially weighted moving average of early mortality after 157 Norwood oper-
ations was 2.3%. Risk factors were an aberrant right subclavian artery, the use and duration of circulatory arrest,
and the duration of total support time. The anatomic subgroup mitral stenosis/aortic atresia and female gender
tended to show an increased early mortality. In the group of patients who required postoperative cardiopulmonary
resuscitation, the ascending aorta was significantly smaller than in the remainder (3.03  1.05 vs 3.63  1.41
mm). Interstage mortality was 15% until the initiation of a home surveillance program in 2005, which has zeroed
it so far. It was significantly higher in the mitral stenosis/aortic atresia subgroup and tended to be higher in patients
who required cardiopulmonary resuscitation after the Norwood operation. The best actuarial survival was ob-
served in the mitral atresia/aortic atresia subgroup.
Conclusion: The Norwood operation can now be performed with lowmortality. Patients with mitral stenosis/aortic
atresia still constitute the most challenging subgroup.(J Thorac Cardiovasc Surg 2010;139:359-65)Earn CME credits at
http://cme.ctsnetjournals.org
Two decades ago, treatment options of hypoplastic left heart
syndrome (HLHS) were limited owing to high mortality
rates.1,2 Therefore, in most centers patients were advised
to either terminate pregnancy or provide compassionate
care after birth. Since then, mortality rates have declined
constantly owing to improvements in surgical technique
and perioperative treatment.3,4 However, the Norwood oper-
ation is still considered a high-risk procedure and interstage
mortality from the Norwood operation to the subsequent
hemi-Fontan operation is still a matter of concern, with mor-
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The Journal of Thoracic and CaThe aim of our study was to analyze the outcome of pa-
tients with HLHS who received their Norwood operation
between 1996 and the end of 2007 and to identify clinical
and anatomic risk factors for adverse early and longer term
outcome.
PATIENTS AND METHODS
Our study population consisted of 157 patients with HLHS as defined by
the Nomenclature Working Group of the International Society of Nomen-
clature of Paediatric and Congenital Heart Disease,7 who were treated in
our institution between January 1996 and December 2007.
We reviewed our HLHS database for data on anatomy, extracardiac le-
sions, surgical and perioperative treatment, perioperative complications,
and death. All parents gave their informed consent to the anonymized anal-
ysis of the data and the study was approved by the local research ethics
committee.
Anatomic Data
On the basis of echocardiography performed before the Norwood op-
eration by two experienced investigators, all patients were assigned to
distinct anatomic subgroups adhering to a classification system proposed
by the International Society of Nomenclature of Paediatric and Congen-
ital Heart Disease and previously used by Tchervenkov,7 Jacobs,8 and
their coworkers. These subgroups were mitral atresia/aortic atresia
(MA/AA), mitral stenosis/aortic stenosis (MS/AS), mitral stenosis/aortic
atresia (MS/AA), and mitral atresia/aortic stenosis (MA/AS). Addition-
ally, the size of the ascending aorta was determined and additive ana-
tomic findings evaluated. The distinction of valve stenosis and atresia
was based on the presence or absence of opening and flow across the
valve. The diagnosis of a restrictive atrial septum was made on the basisrdiovascular Surgery c Volume 139, Number 2 359
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D36Abbreviations and Acronyms0ASCP ¼The Joantegrade selective cerebral perfusionCI ¼ confidence interval
DHCA ¼ deep hypothermic circulatory arrest
HLHS ¼ hypoplastic left heart syndrome
MA/AA ¼ mitral atresia/aortic atresia
MA/AS ¼ mitral atresia/aortic stenosis
MS/AA ¼ mitral stenosis/aortic atresia
MS/AS ¼ mitral stenosis/aortic stenosis
OR ¼ odds ratioof echocardiography in conjunction with clinical data such as PaO2 below 35
mm Hg and/or pulmonary venous congestion detected on radiography.
Preoperative Management
Preoperatively, all children were treated according to a standardized reg-
imen as previously described9 and consisting of strict afterload reduction
with sodium nitroprusside or phentolamine, low-dose prostaglandin E1, fu-
rosemide, enteral feeding, and avoidance of mechanical ventilation or ino-
tropic support. If inotropic support was mandatory or commenced externally
in children with cardiogenic shock, it was terminated as soon as possible.
Surgical Management
The majority of all Norwood operations were performed by a single sur-
geon (n ¼ 148/157). In the period from 1996 until January 2000, deep hy-
pothermic circulatory arrest (DHCA) was used (n ¼ 39). Since then, all
patients (n ¼ 118) were operated on with low-flow antegrade selective ce-
rebral perfusion (ASCP) during the reconstruction of the aortic arch so that
DHCA could be avoided. Until September 1999, the aortic arch was aug-
mented with pulmonary homograft material. From October 1999 onward,
bovine pericardium was used. Pulmonary perfusion was achieved with
a modified Blalock–Taussig shunt, which was placed between the innomi-
nate artery and the bifurcation of the pulmonary arteries, a central aortopul-
monary shunt, or a right ventricular–pulmonary artery conduit (Sano shunt),
which was inserted into the right side of the aorta.
The pH-stat method was used for cooling to a temperature of 18 C and
continued during bypass with an intermittent low-flow strategy. The patient
was rewarmed with the a-stat method. Since January 2000, hemofiltration
has been routinely used.
Postoperative Management
Postoperatively, all patients were continued on afterload reduction ther-
apy, with either phentolamine or sodium nitroprusside. Inotropic support
was achieved with epinephrine and enoximone. For anticoagulation 3 mg/
kg acetylsalicylic acid was routinely given. In October 2005 we introduced
a home surveillance program (n¼ 29) as described by Ghanayem and asso-
ciates10 to reduce interstage mortality.
After the Norwood operation, patients were discharged from the hospital
if they could be fed orally without a gastric tube, were thriving, and had an
oxygen saturation greater than75%.
The indication to perform the hemi-Fontan operation as the second step
of palliation was based on multiple clinical variables taking into account the
patient’s oxygen saturation (<80%) and weight (>5 kg), potential signs of
uncontrollable heart failure, and right ventricular function.
Outcome Measures
Thirty-day mortality was defined as death within the first 30 days of the
Norwood operation regardless of whether in or out of the hospital. Deathurnal of Thoracic and Cardiovascular Surgafter this period and until the subsequent palliative surgery, regardless of
whether in or out of the hospital, was defined as interstage mortality. Actu-
arial survival was calculated with the Kaplan–Meier method.
Additional adverse outcome measures were classified into neurologic
complications (seizures, cerebral hemorrhage, cerebral infarct), hypoxic
and hemodynamic complications (shunt occlusion, cardiac arrhythmias
needing intervention, shock defined as a low cardiac output state needing
pharmacologic resuscitation, bleeding leading to hemodynamic compro-
mise and requiring immediate blood transfusion), cardiopulmonary resusci-
tation including chest compression, and others (liver and kidney
insufficiency as previously defined,9 necrotizing enterocolitis, and sepsis di-
agnosed according to the criteria of the International Consensus Conference
on Pediatric Sepsis).11
Statistical Analysis
Statistical analyses were performed with the statistical software package
SPSS 15.0 (SPSS Inc, Chicago, Ill). Continuous variables are presented as
mean standard deviation or median and range as appropriate, and categor-
ical data are given as count and percentages. Selected continuous variables
were dichotomized to create categorical variables.
Categorical data were analyzed with the c2 or Fisher exact test as appro-
priate. Continuous variables were analyzed with the Student t test after test-
ing for equality of variances with the Levene test. Nonparametric tests for
two independent samples were performed with the Mann–Whitney U test;
for more than two samples, the Kruskal–Wallis test was applied. Cardiopul-
monary support times were evaluated with univariate logistic regression.
For evaluation of risk factors for 30-day and interstage mortality, variables
with a value of P .1 on univariate analysis were entered into a multivariate
stepwise logistic regression analysis model. Results are presented as odd ra-
tios (OR) with 95% confidence intervals (CI). To show variations and
trends over time, we calculated 30-day mortality after the Norwood opera-
tion as exponential weighted moving average. The exponential weighted
moving averagemethodwas applied by de Leval and colleagues12 in a series
of arterial switch operations and used in two studies with patients who had
HLHS by McGuirk and coworkers.5,13 This method emphasizes more re-
cent results by downweighting each previous observation by 5%. CIs
were calculated by the method by Wilson. Survival analysis was performed
by the Kaplan–Meier method, and the Breslow test (generalized Wilcoxon)
was used to test equality of survival distributions on univariate analysis.
Variables with a value of P  0.1 were entered into a stepwise Cox regres-
sion analysis model. All other statistical tests were performed with a level of
significance of 5%.RESULTS
Patient characteristics, including gender, prenatal diagno-
sis, preterm birth weight of 2.5 kg or less, preoperative com-
plications and treatment, anatomic subgroups, additional
cardiovascular anomalies and extracardiac anomalies, and
additional operations between the Norwood and subsequent
hemi-Fontan operation are shown in Table 1. The mean di-
ameter of the ascending aorta was 3.49  1.36 mm. The as-
cending aorta was smallest in patients with MA/AA.Norwood Operation
Details regarding the Norwood operation are displayed in
Table 2. In 143 patients, pulmonary blood flow was estab-
lished with a modified Blalock–Taussig shunt. In 12 patients
with an aberrant right subclavian artery, a central aortopul-
monary shunt was placed and 2 patients were palliated with
a right ventricular–pulmonary artery conduit. In patientsery c February 2010
TABLE 1. Patient characteristics (n ¼ 157)*
General information
Female 56 (35.7)
Male 101 (64.3)
Premature infants 10 (6.4)
2.5 kg 19 (12)
Prenatal diagnosis, yes 72 (45.9)
Preoperative complicationsy
Cardiopulmonary resuscitation 5 (3.2)
Cerebral complications 6 (3.8)
Necrotizing enterocolitis 10 (6.4)
Hepatic/renal failure 13 (8.3)
Sepsis 2 (1.3)
Preoperative treatment
Initial inotropic support 27 (17.2)
Continuous inotropic support 1 (0.6)
Initial mechanical ventilation 43 (27.4)
Continuous mechanical ventilation 11 (7.0)
Pulmonary artery banding 6 (3.8)
Atrial septectomy 2 (1.3)
Procedures between Norwood and hemi-Fontan
operations
Revision/replacement of the modified BT shunt 20 (12.8)
Rethoracotomy for uncontrollable bleeding 4 (2.6)
Rethoracotomy to reduce BT shunt size 4 (2.6)
Pulmonary artery banding 1 (0.6)
Abdominal surgery for necrotizing enterocolitis 2 (1.3)
Shunting of a hydrocephalus 1 (0.6)
Fundoplication 1 (0.6)
Anatomic subgroups
MA/AA 70 (44.6)
MS/AS 42 (26.7)
MS/AA 34 (21.7)
MA/AS 11 (7)
Native diameter of the
ascending aortaz
MA/AA (mm) 2.69  0.79
MS/AS (mm) 4.77  1.21
MS/AA (mm) 3.14  0.90
MA/AS (mm) 4.77  1.47
Additional cardiovascular anomaliesy
Restrictive atrial septal defect 9 (5.7)
Ventricular septal defect 18 (11.5)
Tricuspid valve insufficiency 16 (10.2)
Aberrant right subclavian artery 13 (8.3)
Truncus bicaroticus 1 (0.6)
Pulmonary valve anomaly 5 (3.2)
Systemic venous anomaly 13 (8.3)
Total anomalous pulmonary
venous connection
4 (2.5)
Partial anomalous pulmonary
venous connection
4 (2.5)
Extracardiac anomaliesy
Genetic anomalies 3 (1.9)
Congenital hydrocephalus 2 (1.3)
Renal dysplasia 1 (0.6)
Intestinal malrotation/nonrotation 3 (1.9)
TABLE 1. Continued
Esophageal atresia 1 (0.6)
Laryngomalacia 1 (0.6)
Congenital hypothyroidism 1 (0.6)
Coagulation disorder 8 (5.1)
BT, Blalock–Taussig;MA/AA,mitral atresia/aortic atresia;MS/AS, mitral stenosis/aor-
tic stenosis;MS/AA,mitral stenosis/aortic atresia;MA/AS,mitral atresia/aortic stenosis.
*Data are given with numbers and percentage in parentheses. yMultiple diagnoses per
patient are possible. zData are given as mean SD. The group with MA/AA had a sig-
nificantly smaller ascending aorta than MS/AS, MS/AA, and MA/AS.
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and mean duration of cardiac ischemia was 72.9 15.3 min-
utes, which was significantly lower in patients with ASCP
(54.9  17.3 minutes). In the subgroup of patients operated
on without ASCP, DHCA time was inversely related to the
time interval from the Norwood operation to analysis of the
data (follow-up time) (r ¼ 0.47, P< .01). In the entire
patient cohort, cardiac ischemia time was inversely related
with follow-up time (r ¼0.67, P< .001). Total support
time did not show differences between patients with
and without ASCP. The chest was left primarily open in
22 patients.
Postoperative Care
For the whole group the median duration of postoperative
ventilation was 72 hours (16–1191 hours), without signifi-
cant differences between anatomic subgroups. The median
length of stay after the Norwood operation was 42 days
(12–353 days). Fifteen patients could not be discharged be-
fore the hemi-Fontan operation.
Postoperative Complications
Postoperative complications were observed in 89
(56.7%) patients after the Norwood operation. Their fre-
quency did not show significant differences between the
anatomic subgroups (Table 3). No patient received extracor-
poreal membrane oxygenator support after the Norwood op-
eration. Evaluation of risk factors for postoperative
complications showed that cardiopulmonary resuscitation
tended to be more likely in patients with aortic atresia
(MA/AA and MS/AA vs MS/AS and MA/AS [OR 2.42,
95% CI 0.98–5.99]). Those patients who required a cardio-
pulmonary resuscitation had significantly smaller diameters
of the ascending aorta (3.03 1.05 vs 3.63 1.41 mm). The
use and the duration of DHCA were significantly related to
cerebral complications.
Subsequent Procedures and Follow-up
As the second step of the palliation, a hemi-Fontan oper-
ation was performed in 119 patients with 116 survivors at
a median age of 4.5 months (1.2–45.7 months). Eight
patients died during the interstage period before completion
of the Fontan circulation. The latter was performed inrdiovascular Surgery c Volume 139, Number 2 361
TABLE 2. Details regarding the Norwood operation
Norwood (n ¼ 157)
Median age at operation (d) 7 (1–57)
Weight at operation (kg) 3.2  0.5
Shunt diameter 3 mm (n) 56
Shunt diameter 3.5 mm (n) 78
Shunt diameter 4.0 mm (n) 21
Shunt diameter 5 mm* (n) 2
Index shunt size (mm2/kg) 2.88  0.58
Bypass time (min) 135 (31–265)
Aortic crossclamp (min) 42 (0–80)
Deep hypothermic arrest (min) 7 (0–127)
Cardiac ischemia time (min) 59.36  18.53
Total support time (min) 152.06  31.33
*Patients with right ventricular–pulmonary artery conduit.
TABLE 3. Complications after the Norwood operation according to
anatomic subgroups*
MA/AA
(n ¼ 70)
MS/AS
(n ¼ 42)
MS/AA
(n ¼ 34)
MA/AS
(n ¼ 11)
P
value
No. of patients
with complications
36 21 23 9 .116
Cardiopulmonary
resuscitation
17 6 11 1 .205
Hypoxic, hemodynamic
complications
30 13 12 4 .651
Cerebral complications 4 3 3 2 .448
Other 12 4 9 4 .091
MA/AA, Mitral atresia/aortic atresia; MS/AS, mitral stenosis/aortic stenosis; MS/AA,
mitral stenosis/aortic atresia; MA/AS, mitral atresia/aortic stenosis. *Multiple compli-
cations per patient were possible.
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death but with 2 late deaths. Three patients underwent trans-
plantation during the study period (1 after the Norwood op-
eration; 2 after the hemi-Fontan operation). Follow-up was
complete for all surviving patients (n ¼ 110) with a median
follow up period of 5.09 years (0.13–11.83 years).
The size of the Blalock–Taussig shunt affected the timing
of the hemi-Fontan operation. We found an almost signifi-
cant difference in the shunt index between the group of pa-
tients who were younger than or equal to the median age of
4.5 months at hemi-Fontan operation compared with those
older than 4.5 months (indexed shunt size in patients aged
4.5 months versus>4.5 months: 2.78  0.31 vs 3.0 
0.8 mm2/kg, P ¼ .05).
Thirty-day mortality
Thirty-day mortality was 21% in the first 3 years and
2.5% in the last 3 years. After 157 Norwood operations,
the exponential weighted moving average estimated a 30-
day mortality rate of 2.3% (Figure 1). Univariate analysis
identified an aberrant right subclavian artery and the use of
DHCA as significant risk factors for 30-day mortality (Table
4). In addition, duration of DHCA, cardiac ischemic time,
and total support time were significantly related to 30-day
mortality on univariate logistic regression analysis. A ten-
dency toward a higher risk for death within 30 days was ob-
served in the anatomic subgroupMS/AA (OR, 2.64; 95%CI,
0.94–7.44) and for female gender (OR, 2.61; CI, 0.97–7.06).
On multivariate regression analysis, the lack of ASCP
(OR, 4.85; 95% CI, 1.61–14.58) and an increase in total
support time (OR, 1.41; 95% CI, 1.16–1.72 per 15-minute
increase) were independently associated with 30-daymortal-
ity after the Norwood operation.
Interstage Mortality
Interstage mortality was 15% (n ¼ 11/106) and dropped
to 0% (n¼ 0/29) after the initiation of our home surveillance
program.362 The Journal of Thoracic and Cardiovascular SurgIn Table 4, the results of the univariate analysis of risk
factors for interstage mortality are shown. A significantly
higher risk for interstage mortality was found for the ana-
tomic subgroup MS/AA (OR, 4.09; 95% CI, 1.36–12.35).
Patients with MA/AA showed favorable outcomes during
the interstage period compared with the other subgroups.
There was a relatively high risk of interstage mortality in pa-
tients who required cardiopulmonary resuscitation during
the hospital course after the Norwood operation (OR, 2.93;
95% CI, 0.90–9.53).Actuarial Survival
Overall actuarial survival was 73.5% at 1 year and 68.4%
at 5 years. Relevant differences were noticed between ana-
tomic subgroups (Figure 2). One-year survival (81.9%)
and 5-year survival (76.8%) were highest for patients with
MA/AA. For the other subgroups, survival was lower
(MS/AS: 78.2% and 69.7%; MA/AS: 63.6% and 50.9%;
MS/AA: 55.6% and 55.6%).
Risk factors influencing long-term survival after a success-
ful Norwood operation were analyzed excluding patients
who died within 30 days after the Norwood operation. On
univariate analysis, the anatomic subgroup significantly
influenced actuarial survival. On pairwise analysis, patients
with MA/AA had significantly higher survivals than patients
with MS/AA. Between the remaining subgroups, no signif-
icant differences were found.
Multivariate Cox regression analysis revealed that pa-
tients withMA/AA had a lower risk for death after a success-
ful Norwood operation compared with the MS/AA and MA/
AS subgroups. Postoperative cardiopulmonary resuscitation
and an ascending aorta less than 2 mm also adversely af-
fected survival after successful Norwood operation on mul-
tivariate analysis (Table 5).DISCUSSION
Over a period of 12 years, early mortality of the Norwood
operation could be reduced in our institution from 21% inery c February 2010
FIGURE 1. Thirty-day mortality after the Norwood operation. Exponen-
tially weighted moving average with 95% confidence intervals.
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cordance with this, the exponentially weighted early mortal-
ity decreased continuously to 2.3% at the end of the study
period. A notable decrease in early mortality after the Nor-
wood procedure has also been reported by other groups.3,5Improvement in Management
The reasons for this achievement are certainly numerous,
with an overall gain of experience during the study period
being one reason. The inverse relationships between the car-
diac ischemia time and DHCA time with the follow-up inter-
val do support this conjecture. However, strict adherence to
a uniform preoperative treatment strategy with avoidance of
mechanical ventilation and inotropic support9 and sufficient
afterload reduction have certainly substantially contributed.
Key in our postoperative management was an adequate
afterload reduction. It has been shown by Tweddell and co-
workers3 that a sufficient afterload reduction helps to avoid
an abrupt increase in systemic vascular resistance in the
postoperative course and, in conjunction with manipulating
inflammatory response, accounts for the reduction in early
mortality. Other centers reported that the use and duration
of DHCA are significant contributors to early mortality.3,6,14
With the introduction of ASCP in 2000, we initially reduced
and eventually avoided DHCA, hence eliminating this risk
factor. The increased risk for early mortality with longer to-
tal support time described by Gaynor and colleages15 and
was confirmed by our study.Anatomic Risk Factors
The anatomy of MS/AA was associated with an increased
risk for early death after the Norwood operation, a finding
also reported by others.16-18 Adverse left ventricular–right
ventricular interaction might contribute to this finding.
Sugiyama and associates19 revealed myocardial necrosis, cal-
cification, and fibrosis in the left ventricle of patients withMS/
AA and noticed impaired posterior wall motion of the right
ventricle with compensatory hyperkinesias of the anterior
wall. Additionally, endocardial fibroelastosis, endocardial
thickness, and myocardial fibrosis were more pronounced inThe Journal of Thoracic and Cathese left ventricles comparedwith those in the other anatomic
subgroups. It can therefore be assumed, that the left ventricle in
the setting ofMS/AA is a functional burden to the right ventri-
cle (‘‘piggyback ventricle’’) with deleterious effects on out-
come. Further research on the functional impact of the
hypoplastic left ventricle on right ventricular function is
clearly warranted.Additionally, coronary artery abnormalities
such as coronary fistulas that were described by Vida and co-
workers17 potentially affect myocardial perfusion in patients
with MS/AA. As such abnormalities are sometimes difficult
to visualize by echocardiography, coronary anomalies were
not included in the retrospective risk factor analysis presented
here.
In accordance with Ishino and coworkers,14 we found the
presence of an aberrant right subclavian artery to be a risk
factor for 30-day mortality. Patients with this anomaly out
of necessity received a central aortopulmonary shunt from
the ascending aorta to the bifurcation of the pulmonary ar-
teries. The proximity of this shunt to the origin of the coro-
nary system certainly contributed to an impaired coronary
perfusion by runoff into the aortopulmonary shunt during
diastole. Children with this anatomy probably benefit from
an right ventricular–pulmonary artery conduit.
In contrast to previous reports by Tweddell,3 McGuirk,13
and their associates, we could not identify a birth weight less
than 2.5 kg as a risk factor for early death after the Norwood
operation.
Impact of Complications on Outcome
Postoperative complications were common in our cohort
although comparable with other contemporary reports.20
Patients who required cardiopulmonary resuscitation had sig-
nificantly smaller diameters of the ascending aorta, indicating
that myocardial ischemia and impaired ventricular dysfunc-
tion led to this complication. Cerebral complications de-
creased significantly with the avoidance of DHCA, which
might improve neurodevelopmental outcome.21,22
Reduction of Interstage Mortality
Interstagemortality between the Norwood and subsequent
hemi-Fontan operationwas 15% and comparable with previ-
ous reports from other centers.3,6,23 Again, the anatomy of
MS/AA was a risk factor for death in the interim between
the two operations, and we presume a similar pathophysiol-
ogy for this. Additionally, cardiopulmonary resuscitation re-
quired during the hospital stay after the Norwood operation
was also a risk factor for interstage death. An unbalanced re-
lationship between the pulmonary and systemic circulations
with subsequent myocardial ischemia and right ventricular
dysfunction are potential mechanisms leading to hemody-
namic instability and finally death. Fortunately, since the in-
troduction of a home surveillance program in October 2005,
interstage mortality has decreased significantly. As part of
the program, all parents received strict guidelines to contactrdiovascular Surgery c Volume 139, Number 2 363
TABLE 4. Univariate risk factor analysis for 30-day and interstage mortality
Thirty-day mortality (n ¼ 157) Interstage mortality (n ¼ 135)
Risk factor OR (95% CI) OR (95% CI)
Absent prenatal diagnosis 1.38 (0.51–3.77) 1.14 (0.40–3.27)
Gender (female vs male) 2.61 (0.97–7.06) 0.93 (0.30–2.87)
Premature infant 0.85 (0.10–7.13) 1.07 (0.12–9.28)
MA/AA 0.59 (0.21–1.65) 0.14 (0.03–0.65)
MS/AS 0.76 (0.24–2.45) 1.24 (0.40–3.83)
MS/AA 2.64 (0.94–7.44) 4.09 (1.36–12.35)
MA/AS 0.76 (0.09–6.30) 1.98 (0.38–10.28)
Diameter ascending aorta  2 mm 2.16 (0.70–6.70) 2.00 (0.58–6.93)
Tricuspid insufficiency 1.12 (0.23–5.37) 0.54 (0.07–4.46)
Restrictive atrial septum 0.96 (0.11–8.18) 1.26 (0.14–11.16)
Aberrant right subclavian artery 4.13 (1.12–15.15) 2.29 (0.43–12.10)
Preoperative complications 0.87 (0.23–3.22) 0.96 (0.25–3.66)
Preoperative inotropic support 0.96 (0.26–3.57) 0.29 (0.04–2.34)
Preoperative ventilation 1.02 (0.34–3.06) 0.34 (0.07–1.59)
Weight at operation  2.5 kg 0.90 (0.19–4.25) 1.73 (0.44–6.84)
DHCA vs ASCP 3.63 (1.33–9.96) 1.71 (0.54–5.37)
Duration of CPB (per 15-minute increase) 1.03 (0.87–1.22) 0.94 (0.78–1.14)
Duration of ACC (per 15-minute increase) 0.79 (0.58–1.07) 0.83 (0.60–1.17)
Duration of DHCA (per 15-minute increase) 1.37 (1.11–1.69) 0.32 (0.88–1.46)
Duration of CIT (per 15-minute increase) 1.87 (1.23–2.85) 1.06 (0.67–1.68)
Duration of TSPT (per 15-minute increase) 1.36 (1.12–1.65) 1.01 (0.77–1.34)
Postoperative cardiopulmonary resuscitation NA 2.93 (0.90–9.53)
Postoperative hypoxemia, rhythm complications NA 0.74 (0.22–2.44)
Postoperative cerebral complications NA 0.81 (0.10–6.89)
Other postoperative complications NA 1.75 (0.51–6.02)
OR, Odds ratio; CI, confidence interval; MA/AA, mitral atresia/aortic atresia; MS/AS, mitral stenosis/aortic stenosis; MS/AA, mitral stenosis/aortic atresia; MA/AS, mitral atresia/
aortic stenosis; DHCA, deep hypothermic circulatory arrest; ASCP, antegrade selective cerebral perfusion; CPB, cardiopulmonary bypass; ACC, aortic crossclamp; CIT, cardiac
ischemic time; TSPT, total support time; NA, not applicable.
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saturation andwere contacted on a weekly basis.We are con-
fident that this program is sufficient to detect any imbalance
between pulmonary and systemic perfusion so that hospital
admission and treatment can be initiated in time.Time after Norwood procedure (years)
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FIGURE 2. Kaplan–Meier actuarial survival curves between anatomic
subgroups.MA/AA,Mitral atresia/aortic atresia;MS/AS,mitral stenosis/aor-
tic stenosis;MS/AA,mitral stenosis/aortic atresia;MA/AS,mitral atresia/aor-
tic stenosis.Improvement of Actuarial Survival
Jonas and colleagues16 reported on the early experience
with the Norwood operation from the Boston group. They
described the best long-term survival for patients with
HLHS in the subgroup with MS/AS and the worst in the sub-
group with MA/AA. This is in contrast to our findings, in
which 1-year and 5-year survivals were superior in the sub-
group of patients with MA/AA. However, Jonas and co-
workers16 reported on an early era of the Norwood
operation, and treatment strategies, especially the technique
of aortic arch reconstruction and anastomosis of the native
hypoplastic ascending aorta with the neoaorta, have been
modified since.
Improvements in this crucial part of the Norwood opera-
tion may well have reduced the risk for coronary stenosis
and subsequent myocardial ischemia, especially in patients
with a small ascending aorta universally present in the
MA/AA subgroup. Indeed, Bartram, Grunenfelder, and364 The Journal of Thoracic and Cardiovascular SurgVan Praagh24 reported an analysis of postmortem cases of
the early Boston series of HLHS patients and found that a ste-
nosis at the site of the anastomosis of the native hypoplastic
ascending aorta with the neoaorta was the most common
cause of death at that time.ery c February 2010
TABLE 5. Factor influencing long-term survival after successful
Norwood operation (multivariate Cox regression analysis)
Factor Hazard ratio 95% CI P value
MS/AS vs MA/AA 2.939 0.961–8.991 .059
MS/AA vs MA/AA 4.176 1.489–11.715 .012
MA/AS vs MA/AA 14.661 3.550–60.548 <.001
Diameter ascending
aorta  2 mm
3.664 1.327–10.008 .012
Postoperative cardiopulmonary
resuscitation
8.089 2.295–28.514 .001
CI, Confidence interval;MS/AS, mitral stenosis/aortic stenosis;MA/AA, mitral atresia/
aortic atresia; MS/AA, mitral stenosis/aortic atresia; MA/AS, mitral atresia/aortic
stenosis.
Furck et al Congenital Heart Disease
C
H
DThe restriction of shunt size to avoid pulmonary overcir-
culation might also have contributed to improved long-term
survival. We used smaller modified Blalock–Taussig shunts
than some other groups, although this will probably affect
the timing of the second stage procedure.3Limitations of the Study
Although data were collected prospectively, our patients
were not randomly allocated to different therapeutic groups.
A clear definition of distinct risk factors for 30-day, inter-
stage, and long-term mortality is therefore hampered. Unfor-
tunately, we cannot report on any postmortem data and
therefore the cause of death, especially in the interstage pe-
riod, remains unclear. Quantitative data on ventricular func-
tion are also lacking in our study but are clearly warranted
to delineate the impact of the remnants of the left ventricle
on right ventricular performance.
CONCLUSION
Thirty-day and interstage mortality after the Norwood op-
eration for HLHS could remarkably be reduced in our series
over a period of 12 years. The overall gain of experience, the
introduction of standardized perioperative treatment proto-
cols, and the initiation of a home surveillance program con-
tributed to this improvement. However, patients with an
anatomy ofMS/AA still constitute the most challenging sub-
group of HLHS with the lowest longer term survival.
We dedicate this work to Prof. Paul H. Heintzen (1925–2009),
the founder and first director of the Department of Paediatric Car-
diology, University-Hospital of Schleswig-Holstein, Campus
Kiel, Kiel, Germany.
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